Optimization of treatment of irritable bowel syndrome in children

Journal Title: Здоров`я дитини - Year 2019, Vol 14, Issue 0

Abstract

Background. Factors that trigger several pathophysiological mechanisms may simultaneously be involved in the occurrence of irritable bowel syndrome (IBS). Disorders of the intestinal microbiota play a significant role in the pathogenesis of the disease in children, given the characteristics of the child’s body. Changes in the composition of the intestinal microflora may be accompanied by movement disorders and impaired sensory sensitivity of the intestines, which form the basis for the formation of pain, dyspeptic manifestations and stool disorders. The lack of effect from the treatment of IBS may be due to the presence of violations of the intestinal biocenosis in the child; therefore, in accordance with the recommendations of the Rome IV criteria, it is necessary to correct the intestinal microflora. The purpose is to study the effectiveness of synbiotic Optilact® in the treatment of irritable bowel syndrome in children. Materials and methods. Thirty-three children aged 8 to 14 years with irritable bowel syndrome (variant with constipation) were examined. The diagnosis was made on the basis of clinical, paraclinical, laboratory and instrumental studies. The dietary supplement Optilact® was prescribed in order to relieve the main complaints — constipation, flatulence, to reduce pain symptoms and improve the general condition of the patient. The effectiveness of therapy was evaluated on the basis of the clinical dynamics of pain and dyspeptic complaints, reduction of constipation. The dyna­mics of coprological data was assessed by the end of the course of dietary supplement administration. Results. The findings indicate the feasibility and effectiveness of synbiotic Optilact® in children with irritable bowel syndrome (variant with constipation). The positive dynamics of pain and dyspeptic manifestations, the absence of side effects make it possible to use it in children. Conclusions. The use of the dietary supplement Optilact® in the comprehensive therapy of patients with IBS (variant with constipation) reduces pain and dyspeptic manifestations of the disease, eliminates constipation.

Authors and Affiliations

O. B. Hanzii, L. G. Voloshyna, O. M. Вabadzhanian, N. V. Pavlenko, O. V. Drachevska

Keywords

Related Articles

Persistent Herpes Virus Infections and Their Role in the Incidence in Frequently and Chronically Ill Children

We analyzed data on the role of herpes virus persistent infections in recurrent course of respiratory diseases in frequently and chronically ill children. The approaches to the etiopathogenic therapy and rehabilitation w...

Electronic cigarette smoking as a health risk factor for modern adolescents

Background. In our country, the reduced prevalence of usual cigarette smoking among the adolescents and the increased prevalence of alternative types of smoking, particularly the electronic cigarettes, is established. Th...

Experience of Biosporin-Biopharma Application in the Correction of Functional Gastrointestinal Disorders in Infants

Efficacy of probiotic preparation Biosporin-Biopharma application in the treatment of intestinal colic in infants has been investigated in the paper. It has been proved that on the background of therapy with Biosporin-Bi...

Clinical-Anamnestic Features and Evaluation of Control for Exercise-Induced Bronchial Asthma in Schoolchildren with Xenobiotics Biotransformation Genes Polymorphism

Complex clinical and spirographic investigation of schoolchildren suffering from exercise-induced bronchial asthma was carried out depending on the presence or the absence of genes polymorphism of the enzymes of glutatio...

Features of the course of broncho-obstructive syndrome in young children depending on the level of vitamin D

Background. Diseases of the respiratory tract, including broncho-obstructive syndrome (BOS), are common pathology in childhood. It is known that the incidence and severity of respiratory diseases correlates with the leve...

Download PDF file
  • EP ID EP565804
  • DOI 10.22141/2224-0551.14.0.2019.165524
  • Views 73
  • Downloads 0

How To Cite

O. B. Hanzii, L. G. Voloshyna, O. M. Вabadzhanian, N. V. Pavlenko, O. V. Drachevska (2019). Optimization of treatment of irritable bowel syndrome in children. Здоров`я дитини, 14(0), 77-82. https://europub.co.uk/articles/-A-565804